Ocular Therapeutix, INC Form 4 insider transactions

Ocular Therapeutix Chief Strategy Officer Sanjay Nayak sold 1,878 shares of common stock at a weighted average price of $12.04 to cover tax withholding obligations from RSU vesting.

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, pre-reported future sales for tax obligations and a transfer of shares to an irrevocable trust.

Ocular Therapeutix's Chief Development Officer, Peter Kaiser, sold 3,007 shares of common stock at a weighted average price of $12.02 to cover tax withholding obligations related to restricted stock unit vesting.

Ocular Therapeutix's Chief Scientific Officer, Jeffrey S. Heier, sold 3,469 shares of common stock at a weighted average price of $12.04 to cover tax withholding obligations from restricted stock unit vesting.

Ocular Therapeutix's Chief Business Officer, Namrata Saroj, sold 25,865 shares of common stock at a weighted average price of $10.74 to cover tax withholding obligations related to RSU vesting.

Ocular Therapeutix's Chief Legal Officer, Todd Anderman, sold 11,132 shares of common stock at a weighted average price of $12.34 to cover tax withholding obligations related to RSU vesting.

Ocular Therapeutix's Chief Development Officer, Peter Kaiser, sold 9,653 shares of common stock at a weighted average price of $11.03 to cover tax obligations from restricted stock unit vesting.

Ocular Therapeutix Chief Scientific Officer Jeffrey S. Heier sold 10,502 shares of common stock at a weighted average price of $11.04 to cover tax withholding obligations related to restricted stock unit vesting.

Ocular Therapeutix's Executive Chairman, President, and CEO, Pravin Dugel, transferred 49,754 shares of common stock to his spouse as a gift.

Ocular Therapeutix's CFO and COO, Donald Notman, sold 1,066 shares of common stock at a weighted average price of $12.43 to cover tax obligations related to RSU vesting.

Ocular Therapeutix's Chief Development Officer, Peter Kaiser, sold 3,011 shares of common stock at a weighted average price of $12.04 to cover tax withholding obligations related to restricted stock unit vesting.

Ocular Therapeutix's Chief Strategy Officer, Sanjay Nayak, sold 1,885 shares of common stock at an average price of $12.04 to cover tax withholding obligations.

Ocular Therapeutix's Chief Scientific Officer, Jeffrey S. Heier, sold 3,063 shares of common stock at a weighted average price of $12.04 to cover tax withholding obligations.

Ocular Therapeutix's Executive Chairman, President, and CEO, Pravin Dugel, sold 21,494 shares of common stock to cover tax withholding obligations related to RSU vesting.

Ocular Therapeutix's Chief Medical Officer, Nadia Waheed, received grants of 40,363 restricted stock units and 122,923 stock options as part of her compensation.

Ocular Therapeutix's Executive Chairman, Pravin Dugel, transferred 250,361 shares to a trust, retaining beneficial ownership.

Ocular Therapeutix, Inc. Executive Chairman, President, and CEO Pravin Dugel has been granted 2.75 million performance stock options, contingent on the company's share price reaching targets between $15.00 and $30.00.

Ocular Therapeutix, Inc. Director Seung Suh Hong was granted 14,000 restricted stock units and 44,000 stock options, increasing his beneficial ownership in the company.

Ocular Therapeutix, Inc. Director Merilee Raines was granted 14,000 restricted stock units and 44,000 stock options as part of her compensation, aligning her interests with shareholders.

Richard L. Lindstrom, M.D., a Director at Ocular Therapeutix, Inc., was granted 14,000 Restricted Stock Units and 44,000 stock options, while also clarifying his beneficial ownership of common stock.

Ocular Therapeutix, Inc. Director Leslie J. Williams was granted 14,000 restricted stock units and 44,000 stock options on June 11, 2025, as part of her compensation.

Ocular Therapeutix, Inc. Director Charles M. Warden was granted 14,000 restricted stock units and 44,000 stock options as part of his compensation, as disclosed in a recent SEC Form 4 filing.

Ocular Therapeutix, Inc. Director Adrienne L. Graves was granted 14,000 restricted stock units and 44,000 stock options on June 11, 2025, aligning her interests with shareholders.

Nadia Waheed, Chief Medical Officer of Ocular Therapeutix, Inc., sold 13,861 shares of common stock for $8.05 per share to satisfy tax withholding obligations related to restricted stock unit vesting.

Ocular Therapeutix's Chief Strategy Officer, Sanjay Nayak, sold 1,862 shares of common stock on May 23, 2025, at a weighted average price of $7.17, to satisfy tax withholding obligations related to RSU vesting.

Peter Kaiser, Chief Development Officer of Ocular Therapeutix, Inc., sold 2,974 shares of common stock for $7.17 per share to satisfy tax withholding obligations related to RSU vesting, as part of a pre-arranged 10b5-1 plan.

Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc., sold 3,024 shares of common stock at a weighted average price of $7.18 to satisfy tax withholding obligations related to restricted stock unit vesting.

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, Inc., sold 21,219 shares of common stock for $7.18 per share to cover tax withholding obligations related to restricted stock unit vesting.

Director Richard L. Lindstrom purchased 10,000 shares of Ocular Therapeutix, Inc. at $6.96 per share on May 8, 2025.

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, sold shares to cover tax obligations related to vesting restricted stock units.